Skip to main content

Home/ Health affairs/ Group items tagged Medicines-affordability-in-England

Rss Feed Group items tagged

pharmacybiz

NPA : Patients go without prescription medicines - 0 views

  •  
    Almost nine in ten community pharmacists in England say they have patients who sometimes go without prescription medicines because they cannot afford the prescription charge levied by the government. Sixty-eight per cent of pharmacists in a National Pharmacy Association (NPA) survey, conducted via email in June 2022, said this has become more frequent in the past year - suggesting that the rising cost of living could be leading more people to miss out on vital medicines. While prescription charge does not apply in Scotland, Wales and Northern Ireland, in England an NHS patients needs to pay £9.35 per item. For patients who need multiples medicines the cost could be exponential and virtually unaffordable amid rising inflation and higher cost of living. The survey found that 89 per cent of pharmacies in England have patients who sometimes go without prescription medicines due to cost. For most pharmacists (74 per cent) this happens one to five times a week. Fifteen per cent said they see such patients from six to 20 times a week.
pharmacybiz

Impact of prescription charges on people in England:RPS - 0 views

  •  
    The result from the Royal Pharmaceutical Society (RPS)'s survey showed that pharmacists witnessed 'the cost of living is having an impact on whether people can afford prescription medicines in England'. RPS has long campaigned to remove prescription charges for people with long-term conditions in England because they create a financial barrier to patients receiving the medicines needed to keep them well. The charge currently stands at £9.35 per item prescrib9ed and an annual rise usually occurs in April. Prescriptions are free for people in Scotland, Wales and Northern Ireland. One in two pharmacists who responded to the survey said they've seen an increase in the last six months in patients asking them which medicines on their prescription they can 'do without' due to affordability issues. One in two pharmacists had seen a rise in people not collecting their prescription, whilst two out of three pharmacists reported an increase in being asked if there was a cheaper, over-the-counter substitute for the medicine they had been prescribed.
pharmacybiz

NHS Prescription Charges Soar: RPS and CPE React - 0 views

  •  
    The Royal Pharmaceutical Society in England (RPS) and Community Pharmacy England (CPE) have raised alarm over the impending increase in NHS prescription charges, slated to take effect from May 1, 2024. The RPS, represented by Chair Tase Oputu, condemned the rise, labeling it a "dark day for patients" who will now face nearly £10 per prescription item. Oputu emphasised the disproportionate impact on individuals with low incomes, citing the "relentless annual increases in prescription charges" as exacerbating the affordability crisis in healthcare. " Every day pharmacists are asked by patients who are unable to afford all the items in their prescription which ones they can 'do without'" she said. She further added that the financial barriers to get vital medicines should not be faced by any one and advocated for "the abolition of prescription charges in England, as has been implemented in other parts of the UK".
pharmacybiz

Crisis Alert: CPE Warns of UK Medicine Shortages - 0 views

  •  
    Community Pharmacy England (CPE) has cautioned that patients in the UK will continue to encounter difficulties in accessing medicines unless the government addresses supply problems and resolves the critical financial state of community pharmacies. CPE Chief Executive Janet Morrison and Mike Dent, Director of Pharmacy Funding, on Monday 19 February, gave evidence to the Health and Social Care Select Committee's Pharmacy Inquiry, highlighting the impact of ongoing medicines supply issues on pharmacies and patients. Morrison indicated that a combination of the ongoing "financial squeeze, operational pressures, and medicines supply and pricing issues" has left pharmacy businesses fighting for survival. "As the NHS continues to grapple with wider challenges, this is a battle that patients cannot afford for pharmacies to lose," she said. Morrison warned that if pharmacies continue to close, not only business owners and pharmacy teams will suffer, but patients and local communities will also face the consequences.
pharmacybiz

Rising Patient Declines: Urgent Action Needed on Prescription Charges - 0 views

  •  
    More than a third of pharmacists who participated in a survey said they have seen an increase in patients declining prescriptions due to the cost in the last 12 months. The survey was jointly conducted by the Pharmacists' Defence Association (PDA) and the Royal Pharmaceutical Society (RPS), extending their support for the Prescription Charges Coalition (PCC). Responding to the survey, 90 per cent of pharmacists admitted seeing cases where patients decline all the medicines on a prescription due to cost. Nearly all respondents said they have seen cases where patients declined some of their prescribed medicines and more than a quarter of them have experienced such situation often. They have warned of the impact of prescription charges as patients are denying vital medicines, including those for blood pressure and mental health, inhalers, antibiotics, pain relief, and statins, which can have potential consequences for the individual's health.
pharmacybiz

NHS,Pharma Seal £14B Deal for Affordable Medicine| 2024 VPAG - 0 views

  •  
    The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment. The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028. It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.
1 - 6 of 6
Showing 20 items per page